Engineered T Cells in Synovial Sarcoma: Persistence Pays Off! · Persistence Pays Off! Emily Z....
5
VIEWS 914 | CANCER DISCOVERY AUGUST 2018 www.aacrjournals.org IN THE SPOTLIGHT Engineered T Cells in Synovial Sarcoma: Persistence Pays Off! Emily Z. Keung 1 and Hussein A. Tawbi 2 1 Divison of Surgical Oncology, The University of Texas MD Anderson Can- cer Center, Houston, Texas. 2 Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas. Corresponding Author: Hussein A. Tawbi, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 0430, Houston, TX 77030. Phone: 713-792-6111; Fax: 713-745-1046; E-mail: HTawbi@ mdanderson.org doi: 10.1158/2159-8290.CD-18-0618 ©2018 American Association for Cancer Research. Summary: Synovial sarcoma (SS) is an aggressive malignancy that typically affects adolescents and young adults and is associated with poor prognosis. Although SS has failed to respond to immune checkpoint blockade, other strategies designed to generate an immune response, including adoptive cell therapies targeting the cancer testis antigen NY-ESO-1, have shown encouraging results. In this issue, D’Angelo and colleagues confirm the safety and feasibility of adoptive T-cell therapy with autologous T cells engineered to express NY-ESO-1 c259 , an affinity-enhanced T-cell receptor recognizing an HLA-A2–restricted NY-ESO-1–derived peptide, and demon- strate encouraging antitumor responses in 50% of treated patients, particularly in the setting of persistence of polyfunctional NY-ESO-1 c259 –expressing T cells in circulation for at least 6 months. Cancer Discov; 8(8); 914–7. ©2018 AACR. See related article by D’Angelo et al., p. 944 (11). Synovial sarcoma (SS) is an aggressive malignancy that dis- proportionately affects younger patients. SS represents 10% to 20% of all soft-tissue sarcomas in the adolescent and young adult population, with median age at diagnosis between 20 and 30 years (1). In more than 90% of cases, SS is defined by the presence of the t(X;18)(p11.2;q11.2) translocation, which results in fusion of the SS18 (formerly SYT) gene on chromo- some 18 and one of several synovial sarcoma X ( SSX) genes on chromosome X. The standard treatment for patients with localized SS is complete surgical resection with or without radiotherapy. Metastatic SS is considered more responsive to chemotherapy and targeted agents than other soft-tissue sarcomas, and yet the median overall survival is 15 months and the 5-year survival is less than 5% (2). Despite major advances made in a growing number of malig- nancies (including melanoma, urothelial carcinomas, non– small cell lung carcinoma, and microsatellite instability–high malignancies) with the introduction of immune checkpoint blockade, these agents have been ineffective in SS, in which there is generally a lack of tumor-associated inflammatory infiltrate (3).The basis of immune evasion in SS is unknown, although mechanisms besides those currently targeted by immune checkpoint inhibitors (anti-CTLA4 and anti–PD-1) are likely. Specifically, an early study of ipilimumab in SS was closed early for toxicity and futility (4). SARC028 had a dedi- cated cohort for SS that included 10 patients, of whom only 1 had a short-lived partial response and others progressed rapidly (5). The combination of ipilimumab and nivolumab was also ineffective, although only 2 patients with SS were included (6). As with other translocation-associated tumors, SS has low genetic complexity, including low burden of non- synonymous somatic mutations (1). Although there have been limited attempts to directly tar- get the SS18–SSX oncoprotein in SS (7), recent efforts have focused on targeting NY-ESO-1, a cancer testis antigen that is strongly and diffusely expressed in 70% to 80% of SS (8). Past and ongoing clinical trials of adoptive T-cell therapies (ACT) targeting NY-ESO-1 in metastatic SS have shown promise (Table 1). In 2011, Robbins and colleagues reported the first experience with adoptive transfer of T cells engineered to express NY-ESO-1 c259 , an affinity-enhanced T-cell receptor (TCR) recognizing an HLA-A2–restricted NY-ESO-1/LAGE- 1a–derived peptide, in patients with metastatic melanoma or metastatic SS whose tumors stained strongly for NY-ESO-1 (9). Patients received autologous TCR-transduced T cells plus IL2 following lymphodepletion with fludarabine (25 mg/m 2 / day for 5 days) and cyclophosphamide (60 mg/kg/day for 2 days). Objective responses were observed in 4 of the 6 patients with SS. Neither in this study nor in a subsequent report that included results for an additional 12 patients treated with SS did persistence of engineered T cells 1 month after T-cell infu- sion correlate with response to therapy (10). In this issue of Cancer Discovery, D’Angelo and colleagues (11) evaluated the safety and feasibility of treating patients with metastatic SS expressing NY-ESO-1 with autologous T cells engineered to express NY-ESO-1 c259 without exogenous IL2 following lymphodepletion with fludarabine (30 mg/m 2 / day for 5 days) and cyclophosphamide (60 mg/m 2 /day for 2 days). The overall response rate in this study was 50% (6 of 12 patients), with 1 complete response and 5 partial responses. The median time to initial response was 6.2 weeks (range, 4–9 weeks), and median duration of response was 30.9 weeks (range, 13–72 weeks). Treatment-related ≥ grade Cancer Research. on August 5, 2020. © 2018 American Association for cancerdiscovery.aacrjournals.org Downloaded from
Transcript of Engineered T Cells in Synovial Sarcoma: Persistence Pays Off! · Persistence Pays Off! Emily Z....
VIEWS
914 | CANCER DISCOVERY AUGUST 2018 www.aacrjournals.org
IN THE SPOTLIGHT
Engineered T Cells in Synovial Sarcoma: Persistence Pays Off! Emily Z. Keung 1 and Hussein A. Tawbi 2
1 Divison of Surgical Oncology, The University of Texas MD Anderson Can-cer Center, Houston, Texas. 2 Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas. Corresponding Author: Hussein A. Tawbi, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 0430, Houston, TX 77030. Phone: 713-792-6111; Fax: 713-745-1046; E-mail: [email protected] doi: 10.1158/2159-8290.CD-18-0618 ©2018 American Association for Cancer Research.
Summary: Synovial sarcoma (SS) is an aggressive malignancy that typically affects adolescents and young adults and is associated with poor prognosis. Although SS has failed to respond to immune checkpoint blockade, other strategies designed to generate an immune response, including adoptive cell therapies targeting the cancer testis antigen NY-ESO-1, have shown encouraging results. In this issue, D’Angelo and colleagues confi rm the safety and feasibility of adoptive T-cell therapy with autologous T cells engineered to express NY-ESO-1 c259 , an affi nity-enhanced T-cell receptor recognizing an HLA-A2–restricted NY-ESO-1–derived peptide, and demon-strate encouraging antitumor responses in 50% of treated patients, particularly in the setting of persistence of polyfunctional NY-ESO-1 c259 –expressing T cells in circulation for at least 6 months. Cancer Discov; 8(8); 914–7. ©2018 AACR.
See related article by D’Angelo et al., p. 944 (11).
Synovial sarcoma (SS) is an aggressive malignancy that dis-proportionately affects younger patients. SS represents 10% to 20% of all soft-tissue sarcomas in the adolescent and young adult population, with median age at diagnosis between 20 and 30 years ( 1 ). In more than 90% of cases, SS is defi ned by the presence of the t(X;18)(p11.2;q11.2) translocation, which results in fusion of the SS18 (formerly SYT ) gene on chromo-some 18 and one of several synovial sarcoma X ( SSX ) genes on chromosome X. The standard treatment for patients with localized SS is complete surgical resection with or without radiotherapy. Metastatic SS is considered more responsive to chemotherapy and targeted agents than other soft-tissue sarcomas, and yet the median overall survival is 15 months and the 5-year survival is less than 5% ( 2 ).
Despite major advances made in a growing number of malig-nancies (including melanoma, urothelial carcinomas, non–small cell lung carcinoma, and microsatellite instability–high malignancies) with the introduction of immune checkpoint blockade, these agents have been ineffective in SS, in which there is generally a lack of tumor-associated infl ammatory infi ltrate ( 3 ).The basis of immune evasion in SS is unknown, although mechanisms besides those currently targeted by immune checkpoint inhibitors (anti-CTLA4 and anti–PD-1) are likely. Specifi cally, an early study of ipilimumab in SS was closed early for toxicity and futility ( 4 ). SARC028 had a dedi-cated cohort for SS that included 10 patients, of whom only
1 had a short-lived partial response and others progressed rapidly ( 5 ). The combination of ipilimumab and nivolumab was also ineffective, although only 2 patients with SS were included ( 6 ). As with other translocation-associated tumors, SS has low genetic complexity, including low burden of non-synonymous somatic mutations ( 1 ).
Although there have been limited attempts to directly tar-get the SS18–SSX oncoprotein in SS ( 7 ), recent efforts have focused on targeting NY-ESO-1, a cancer testis antigen that is strongly and diffusely expressed in 70% to 80% of SS ( 8 ). Past and ongoing clinical trials of adoptive T-cell therapies (ACT) targeting NY-ESO-1 in metastatic SS have shown promise ( Table 1 ). In 2011, Robbins and colleagues reported the fi rst experience with adoptive transfer of T cells engineered to express NY-ESO-1 c259 , an affi nity-enhanced T-cell receptor (TCR) recognizing an HLA-A2–restricted NY-ESO-1/LAGE-1a–derived peptide, in patients with metastatic melanoma or metastatic SS whose tumors stained strongly for NY-ESO-1 ( 9 ). Patients received autologous TCR-transduced T cells plus IL2 following lymphodepletion with fl udarabine (25 mg/m 2 /day for 5 days) and cyclophosphamide (60 mg/kg/day for 2 days). Objective responses were observed in 4 of the 6 patients with SS. Neither in this study nor in a subsequent report that included results for an additional 12 patients treated with SS did persistence of engineered T cells 1 month after T-cell infu-sion correlate with response to therapy ( 10 ).
In this issue of Cancer Discovery , D’Angelo and colleagues (11) evaluated the safety and feasibility of treating patients with metastatic SS expressing NY-ESO-1 with autologous T cells engineered to express NY-ESO-1 c259 without exogenous IL2 following lymphodepletion with fl udarabine (30 mg/m 2 /day for 5 days) and cyclophosphamide (60 mg/m 2 /day for 2 days). The overall response rate in this study was 50% (6 of 12 patients), with 1 complete response and 5 partial responses. The median time to initial response was 6.2 weeks (range, 4–9 weeks), and median duration of response was 30.9 weeks (range, 13–72 weeks). Treatment-related ≥ grade
Cancer Research. on August 5, 2020. © 2018 American Association forcancerdiscovery.aacrjournals.org Downloaded from
VIEWS
AUGUST 2018 CANCER DISCOVERY | 915
Table 1. Clinical trials targeting NY-ESO-1
Study name Phase Status Target accrualEstimated primary completion date
Adoptive T-cell therapy NCT01477021 A phase I study to determine the feasibil-
ity of using autologous NY-ESO-1–spe-cifi c CD8 + T cells for the treatment of patients with advanced myxoid/round cell liposarcoma and synovial sarcoma
I Completed 6 September 2013
NCT01343043 A pilot study of genetically engineered NY-ESO-1–specifi c NY-ESO-1 c259 T cells in HLA-A2 + patients with synovial sarcoma
I/II Recruiting 65 October 2018
NCT02869217 Phase Ib study of TBI-1301 (NY-ESO-1–specifi c TCR-gene–transduced autologous T lymphocytes) in patients with solid tumors
I Recruiting 15 March 2018
NCT02457650 Phase I study of malignancies that express NY-ESO-1 with TCR-transduced T cells targeting NY-ESO-1
I Recruiting 36 December 2019
NCT03250325 Study of TBI-1301 (NY-ESO-1 TCR-gene-transduced autologous T lymphocytes) in patients with synovial sarcoma
I/II Recruiting 8 January 2020
NCT01967823 Phase II study of metastatic cancer that expresses NY-ESO-1 using lymphodeplet-ing conditioning followed by infusion of anti–NY-ESO-1 murine TCR-gene–engi-neered lymphocytes
II Recruiting 43 July 2027
NCT03399448 Phase I trial of autologous T cells engi-neered to express NY-ESO-1 TCR and CRISPR gene edited to eliminate endog-enous TCR and PD-1 (NYCE T cells)
I Recruiting 18 January 2033
Vaccine therapy NCT01241162 A phase I trial combining decitabine and
vaccine therapy for patients with relapsed neuroblastoma and sarcoma
I Completed 19 October 2016
NCT02609984 A randomized, open-label, phase II trial of CMB305 (sequentially administered LV305 and G305) and atezolizumab in pa-tients with locally advanced, relapsed, or metastatic sarcoma expressing NY-ESO-1
II Active, not recruiting
88 May 2017
NCT02122861 A phase I, open-label clinical trial evaluat-ing the safety, tolerability, and immuno-genicity of intradermally administered ID-LV305 in patients with locally advanced, relapsed, or metastatic cancer expressing NY-ESO-1
I Active, not recruiting
47 December 2017
NCT03520959 A phase III, randomized, double-blind, placebo-controlled study to determine the effi cacy and safety of CMB305 in un-resectable locally advanced or metastatic NY-ESO-1 + synovial sarcoma following fi rst-line systemic anticancer therapy (Synovate study)
III Not yet open 248
(continued)
Cancer Research. on August 5, 2020. © 2018 American Association forcancerdiscovery.aacrjournals.org Downloaded from
VIEWS
916 | CANCER DISCOVERY AUGUST 2018 www.aacrjournals.org
Study name Phase Status Target accrualEstimated primary completion date
Combination ACT and/or vaccine therapy in combination with other therapy NCT02070406 NY-ESO-1 TCR–engineered adoptive cell
transfer therapy with CTLA4 blockadeI Recruiting 12 July 2019
NCT03450122 A phase I study of cellular adoptive immunotherapy using autologous CD8 + NY-ESO-1–specifi c T cells and the NY-ESO-1 immunostimulatory agents LV305 or CMB305 for patients with sarcoma
I Not yet open 18
Other NCT03515551 A phase I/II study of IMCnyeso, HLA-
A*0201-restricted, NY-ESO-1– and LAGE-1A–specifi c soluble TCR and anti-CD3 bispecifi c molecule, in HLA-A*0201–posi-tive patients with advanced NY-ESO-1 and/or LAGE-1A–positive cancer
I/II Not yet open 63
Table 1. Clinical trials targeting NY-ESO-1 (Continued)
3 adverse events (AE) were reported in 11 of 12 patients. AEs were most commonly cytopenias and hypophosphatemia and likely largely attributable to the lymphodepleting chemo-therapy regimen. However, despite eliminating IL2, 5 patients did experience cytokine release syndrome.
D’Angelo and colleagues show that in all patients the infused NY-ESO-1 c259 T cells not only expand but persist in the circulation, as measured by circulating NY-ESO-1 c259 vec-tor copy levels. Interestingly, higher peak NY-ESO-1 c259 vector copy levels were observed in responders compared with non-responders (median 106,174 vs. 30,601 vector copies/µg). Cir-culating NY-ESO-1 c259 TCR-expressing T cells were detectable in all 7 patients for whom monitoring was continued beyond 200 days (6 responders and 1 nonresponder). Additionally, these engineered NY-ESO-1 c259 T cells remained functional by intracellular cytokine staining and did not express exhaus-tion markers such as PD-1 and LAG3.
Next, D’Angelo and colleagues characterized the memory cell phenotype of NY-ESO-1 c259 T cells both in the manu-factured product prior to infusion and in the circulation at longitudinal time points. NY-ESO-1 c259 T cells in the manufactured product were comprised predominantly of effector memory (CCR7 − CD45RA − ) or effector memory RA + (CCR7 − CD45RA + ) phenotype. Although limited by small patient numbers, there were no distinguishable differences between manufactured products received by responders versus nonresponders. Upon adoptive transfer, the authors observed an increase in central memory (CCR7 + CD45RA − ) and stem cell memory (CCR7 + CD45RA + ) cells among the CD4 + and CD8 + NY-ESO-1 c259 T cells in circulation.
The authors then deeply profi led circulating NY-ESO-1 c259 T cells and tumor biopsy available from 1 patient who achieved a partial response following ACT but later relapsed despite persistence of functional NY-ESO-1 c259 T cells in cir-culation. Circulating NY-ESO-1 c259 T cells from this patient at time of relapse that were exposed to antigen ex vivo were capable of inducing robust killing in the absence of exog-
enous cytokines. There was maintenance of a subset of CCR7 +
and CD45RA + cells that the authors postulate are capable of self-renewal and differentiation and underlie the continued presence of NY-ESO-1 c259 –expressing T cells even beyond 6 months after initial engineered T-cell infusion. Interest-ingly, however, although this patient’s tumor at the time of relapse remained NY-ESO-1–positive, there was no evidence of tumor infi ltration by NY-ESO-1 c259 T cells.
Although this study was limited with respect to availability of baseline, on-treatment, and at-relapse tumor and blood biopsies, the exciting fi ndings reported here by D’Angelo and colleagues highlight the importance and impact of lon-gitudinal biospecimen collection. Future trial designs in the ACT space should incorporate longitudinal tumor and blood biopsies, as analyses of these precious biospecimens will be critically important toward improving our understanding of cellular and molecular processes occurring in patients who respond to therapy as well as elucidating mechanisms of resistance in those who fail to respond.
The remarkable responses observed in this study are in stark contrast to the lack of therapeutic effi cacy of checkpoint block-ade in this malignancy, highlighting the fact that the defect in the immune response appears less dependent on T-cell exhaus-tion or the immunosuppressive microenvironment and more likely to be at the level of immune recognition and evasion. The overall lack of antigenic stimulation in SS perhaps points to strategies to enhance antigen release and presentation either through epigenetic agents, radiotherapy, agonist antibodies, vac-cines, or even intratumoral injectables. In those combinations, there could still be a role for anti-CTLA4 antibodies to augment T-cell priming and activation. It is unclear if PD-1 blockade would still be an attractive approach, although the recent suc-cess of combinations involving chemotherapy and anti–PD-1 antibodies suggests a potential role for such combinations in SS.
An important aspect of this study was the elimination of high-dose IL2 from the regimen with arguably improved out-comes as manifested by the clonal diversity and persistence
Cancer Research. on August 5, 2020. © 2018 American Association forcancerdiscovery.aacrjournals.org Downloaded from
VIEWS
AUGUST 2018 CANCER DISCOVERY | 917
of T cells, as well as the predominance of central memory and stem cell memory cells. This tackles one of the main limitations for the generalizability and wide adoption of ACT beyond a very select population that is capable of tolerating the toxicity of a lymphodepleting regimen and high-dose IL2. This modification to the regimen may expand the pool of eli-gible candidates for this and other ACT approaches. The risk–benefit profile of ACT must still be considered by clinicians, who weigh the potential for improved outcomes against the possibility of treatment-associated toxic effects, when select-ing patients for novel therapies. Correlative studies will also allow identification of prognostic and predictive biomarkers that could improve patient selection for ACT.
In summary, D’Angelo and colleagues demonstrate the safety and feasibility of ACT in patients with autologous T cells engineered to express NY-ESO-1c259 in patients with metastatic SS and observed a 50% clinical response of vari-able durability. The authors demonstrate expansion of the infused NY-ESO-1c259 T cells in the absence of exogenous IL2 in all 12 patients who received therapy as well as persistence of NY-ESO-1c259 TCR-expressing T cells in circulation cor-relating with 6 responders of 7 patients tested. These results suggest that adoptive T-cell therapy can induce a robust antitumor response and give rise to a persistent pool of NY-ESO-1c259 T cells that effect meaningful and durable responses in patients with metastatic SS and can form a back-bone for future therapeutic strategies.
Disclosure of Potential Conflicts of InterestH.A. Tawbi has received honoraria from the speakers bureaus of
BMS, Novartis, Merck, and Genentech/Roche. No potential conflicts of interest were disclosed by the other author.
AcknowledgmentsE.Z. Keung is supported by National Institutes of Health (NIH)
grant T32 CA009599.
Published online August 3, 2018.
REFERENCES 1. Nielsen TO, Poulin NM, Ladanyi M. Synovial sarcoma: recent dis-
coveries as a roadmap to new avenues for therapy. Cancer Discov 2015;5:124–34.
2. Vlenterie M, Litière S, Rizzo E, Marréaud S, Judson I, Gelderblom H, et al. Outcome of chemotherapy in advanced synovial sarcoma patients: review of 15 clinical trials from the European organisation for research and treatment of cancer soft tissue and bone sarcoma group; setting a new landmark for studies in this entity. Eur J Cancer 2016;58:62–72.
3. Pollack SM, He Q, Yearley JH, Emerson R, Vignali M, Zhang Y, et al. T-cell infiltration and clonality correlate with programmed cell death protein 1 and programmed death-ligand 1 expression in patients with soft tissue sarcomas. Cancer 2017;123:3291–304.
4. Maki RG, Jungbluth AA, Gnjatic S, Schwartz GK, D’Adamo DR, Keo-han ML, et al. A pilot study of anti-CTLA4 antibody ipilimumab in patients with synovial sarcoma. Sarcoma 2013;2013:168145.
5. Tawbi HA, Burgess M, Bolejack V, Van Tine BA, Schuetze SM, Hu J, et al. Pembrolizumab in advanced soft-tissue sarcoma and bone sar-coma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial. Lancet Oncol 2017;18:1493–501.
6. D’Angelo SP, Mahoney MR, Van Tine BA, Atkins J, Milhem MM, Jaha-girdar BN, et al. Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): two open-label, non-com-parative, randomised, phase 2 trials. Lancet Oncol 2018;19:416–26.
7. Kawaguchi S, Tsukahara T, Ida K, Kimura S, Murase M, Kano M, et al. SYT-SSX breakpoint peptide vaccines in patients with synovial sar-coma: a study from the Japanese Musculoskeletal Oncology Group. Cancer Sci 2012;103:1625–30.
8. Lai JP, Robbins PF, Raffeld M, Aung PP, Tsokos M, Rosenberg SA, et al. NY-ESO-1 expression in synovial sarcoma and other mesenchy-mal tumors: significance for NY-ESO-1-based targeted therapy and differential diagnosis. Mod Pathol 2012;25:854–8.
9. Robbins PF, Morgan RA, Feldman SA, Yang JC, Sherry RM, Dudley ME, et al. Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J Clin Oncol 2011;29:917–24.
10. Robbins PF, Kassim SH, Tran TL, Crystal JS, Morgan RA, Feldman SA, et al. A pilot trial using lymphocytes genetically engineered with an NY-ESO-1-reactive T-cell receptor: long-term follow-up and cor-relates with response. Clin Cancer Res 2015;21:1019–27.
11. D’Angelo SP, Melchiori L, Merchant MS, Bernstein D, Glod J, Kaplan R, et al. Antitumor activity associated with prolonged persistence of adoptively transferred NY-ESO-1c259T cells in synovial sarcoma. Cancer Discov 2018;8:944–57.
Cancer Research. on August 5, 2020. © 2018 American Association forcancerdiscovery.aacrjournals.org Downloaded from
2018;8:914-917. Cancer Discov Emily Z. Keung and Hussein A. Tawbi Off!Engineered T Cells in Synovial Sarcoma: Persistence Pays
Updated version
http://cancerdiscovery.aacrjournals.org/content/8/8/914
Access the most recent version of this article at:
Cited articles
http://cancerdiscovery.aacrjournals.org/content/8/8/914.full#ref-list-1
This article cites 11 articles, 4 of which you can access for free at:
E-mail alerts related to this article or journal.Sign up to receive free email-alerts
SubscriptionsReprints and
To order reprints of this article or to subscribe to the journal, contact the AACR Publications
Permissions
Rightslink site. (CCC)Click on "Request Permissions" which will take you to the Copyright Clearance Center's
.http://cancerdiscovery.aacrjournals.org/content/8/8/914To request permission to re-use all or part of this article, use this link
Cancer Research. on August 5, 2020. © 2018 American Association forcancerdiscovery.aacrjournals.org Downloaded from
